232 related articles for article (PubMed ID: 33794187)
21. REG3A promotes proliferation and DDP resistance of ovarian cancer cells by activating the PI3K/Akt signaling pathway.
Jiang L; Liu Y; Liu M; Zheng Y; Chen L; Shan F; Ji J; Cao Y; Kai H; Kang X
Environ Toxicol; 2024 Jan; 39(1):85-96. PubMed ID: 37665173
[TBL] [Abstract][Full Text] [Related]
22. Berberine in combination with cisplatin induces necroptosis and apoptosis in ovarian cancer cells.
Liu L; Fan J; Ai G; Liu J; Luo N; Li C; Cheng Z
Biol Res; 2019 Jul; 52(1):37. PubMed ID: 31319879
[TBL] [Abstract][Full Text] [Related]
23. The Hedgehog signaling pathway promotes chemotherapy resistance via multidrug resistance protein 1 in ovarian cancer.
Zhang H; Hu L; Cheng M; Wang Q; Hu X; Chen Q
Oncol Rep; 2020 Dec; 44(6):2610-2620. PubMed ID: 33125122
[TBL] [Abstract][Full Text] [Related]
24. Downregulated expression levels of USP46 promote the resistance of ovarian cancer to cisplatin and are regulated by PUM2.
Xu L; Zhang B; Li W
Mol Med Rep; 2021 Apr; 23(4):. PubMed ID: 33576437
[TBL] [Abstract][Full Text] [Related]
25. VPS33B interacts with NESG1 to suppress cell growth and cisplatin chemoresistance in ovarian cancer.
Ning Y; Zeng Z; Deng Y; Feng W; Huang L; Liu H; Lin J; Zhang C; Fan Y; Liu L
Cancer Sci; 2021 May; 112(5):1785-1797. PubMed ID: 33788346
[TBL] [Abstract][Full Text] [Related]
26. miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting MET.
Chen QY; Jiao DM; Wang J; Hu H; Tang X; Chen J; Mou H; Lu W
Oncotarget; 2016 Apr; 7(17):24510-26. PubMed ID: 27014910
[TBL] [Abstract][Full Text] [Related]
27. miR-29c-3p inhibits autophagy and cisplatin resistance in ovarian cancer by regulating FOXP1/ATG14 pathway.
Hu Z; Cai M; Zhang Y; Tao L; Guo R
Cell Cycle; 2020 Jan; 19(2):193-206. PubMed ID: 31885310
[TBL] [Abstract][Full Text] [Related]
28. Octreotide is the favorable alternative for cisplatin resistance reversal of ovarian cancer in vitro and in nude mice in vivo.
Shen Y; Ren ML; Shi YH; Zhang YX; Cai YL
Eur J Gynaecol Oncol; 2012; 33(6):584-90. PubMed ID: 23327050
[TBL] [Abstract][Full Text] [Related]
29. Baohuoside I inhibits resistance to cisplatin in ovarian cancer cells by suppressing autophagy via downregulating HIF-1α/ATG5 axis.
Zhou Y; Liu T; Wu Q; Wang H; Sun Y
Mol Carcinog; 2023 Oct; 62(10):1474-1486. PubMed ID: 37283234
[TBL] [Abstract][Full Text] [Related]
30. Contributions of the Epidermal Growth Factor Receptor to Acquisition of Platinum Resistance in Ovarian Cancer Cells.
Granados ML; Hudson LG; Samudio-Ruiz SL
PLoS One; 2015; 10(9):e0136893. PubMed ID: 26351843
[TBL] [Abstract][Full Text] [Related]
31. [Establishment and biological characteristics of a platinum-resistance nude mouse model in epithelial ovarian cancer].
Shi L; Yu H; Zhang W; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):523-30. PubMed ID: 25327735
[TBL] [Abstract][Full Text] [Related]
32. NCX-4016, a nitro-derivative of aspirin, inhibits EGFR and STAT3 signaling and modulates Bcl-2 proteins in cisplatin-resistant human ovarian cancer cells and xenografts.
Selvendiran K; Bratasz A; Tong L; Ignarro LJ; Kuppusamy P
Cell Cycle; 2008 Jan; 7(1):81-8. PubMed ID: 18196976
[TBL] [Abstract][Full Text] [Related]
33. Stephania Tetrandra and Ginseng-Containing Chinese Herbal Formulation NSENL Reverses Cisplatin Resistance in Lung Cancer Xenografts.
Jin L; Xu M; Luo XH; Zhu XF
Am J Chin Med; 2017; 45(2):385-401. PubMed ID: 28231742
[TBL] [Abstract][Full Text] [Related]
34. cRGD-targeted heparin nanoparticles for effective dual drug treatment of cisplatin-resistant ovarian cancer.
Liang X; Yang Y; Huang C; Ye Z; Lai W; Luo J; Li X; Yi X; Fan JB; Wang Y; Wang Y
J Control Release; 2023 Apr; 356():691-701. PubMed ID: 36933699
[TBL] [Abstract][Full Text] [Related]
35. Noscapine Increases the Sensitivity of Drug-Resistant Ovarian Cancer Cell Line SKOV3/DDP to Cisplatin by Regulating Cell Cycle and Activating Apoptotic Pathways.
Shen W; Liang B; Yin J; Li X; Cheng J
Cell Biochem Biophys; 2015 May; 72(1):203-13. PubMed ID: 25510462
[TBL] [Abstract][Full Text] [Related]
36. Restoration of microRNA-708 sensitizes ovarian cancer cells to cisplatin via IGF2BP1/Akt pathway.
Qin X; Sun L; Wang J
Cell Biol Int; 2017 Oct; 41(10):1110-1118. PubMed ID: 28685895
[TBL] [Abstract][Full Text] [Related]
37. ABT737 reverses cisplatin resistance by targeting glucose metabolism of human ovarian cancer cells.
Xu Y; Gao W; Zhang Y; Wu S; Liu Y; Deng X; Xie L; Yang J; Yu H; Su J; Sun L
Int J Oncol; 2018 Sep; 53(3):1055-1068. PubMed ID: 30015875
[TBL] [Abstract][Full Text] [Related]
38. Exon 4 deletion variant of epidermal growth factor receptor enhances invasiveness and cisplatin resistance in epithelial ovarian cancer.
Zhang P; Zhang P; Zhou M; Jiang H; Zhang H; Shi B; Pan X; Gao H; Sun H; Li Z
Carcinogenesis; 2013 Nov; 34(11):2639-46. PubMed ID: 23764753
[TBL] [Abstract][Full Text] [Related]
39. MicroRNA-95-3p serves as a contributor to cisplatin resistance in human gastric cancer cells by targeting EMP1/PI3K/AKT signaling.
Ni Q; Zhang Y; Tao R; Li X; Zhu J
Aging (Albany NY); 2021 Mar; 13(6):8665-8687. PubMed ID: 33714198
[TBL] [Abstract][Full Text] [Related]
40. FGFR3-TACC3 fusion proteins act as naturally occurring drivers of tumor resistance by functionally substituting for EGFR/ERK signaling.
Daly C; Castanaro C; Zhang W; Zhang Q; Wei Y; Ni M; Young TM; Zhang L; Burova E; Thurston G
Oncogene; 2017 Jan; 36(4):471-481. PubMed ID: 27345413
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
